Biocept, Inc. (BIOC): Price and Financial Metrics


Biocept, Inc. (BIOC): $0.76

0.00 (-0.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BIOC Stock Summary

  • With a market capitalization of $13,067,018, BIOCEPT INC has a greater market value than only 4.4% of US stocks.
  • BIOC's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.1 -- higher than only 1.5% of US-listed equities with positive expected earnings growth.
  • In terms of twelve month growth in earnings before interest and taxes, BIOCEPT INC is reporting a growth rate of -788.84%; that's higher than only 2.24% of US stocks.
  • Stocks that are quantitatively similar to BIOC, based on their financial statements, market capitalization, and price volatility, are UDMY, WEAV, AUPH, USER, and KRMD.
  • BIOC's SEC filings can be seen here. And to visit BIOCEPT INC's official web site, go to biocept.com.

BIOC Valuation Summary

  • BIOC's price/sales ratio is 0.3; this is 85% lower than that of the median Healthcare stock.
  • BIOC's EV/EBIT ratio has moved up 6 over the prior 107 months.

Below are key valuation metrics over time for BIOC.

Stock Date P/S P/B P/E EV/EBIT
BIOC 2022-11-25 0.3 0.5 -0.8 -0.5
BIOC 2022-11-23 0.3 0.5 -0.8 -0.5
BIOC 2022-11-22 0.3 0.5 -0.8 -0.5
BIOC 2022-11-21 0.3 0.5 -0.9 -0.5
BIOC 2022-11-18 0.2 0.4 -1.2 -0.3
BIOC 2022-11-17 0.2 0.4 -1.2 -0.3

BIOC Growth Metrics

    Its 5 year cash and equivalents growth rate is now at 366.3%.
  • Its 4 year net income to common stockholders growth rate is now at -49.94%.
  • Its year over year cash and equivalents growth rate is now at 94.16%.
Over the past 15 months, BIOC's revenue has gone down $4,781,597.

The table below shows BIOC's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 50.11914 -7.483973 -16.53611
2022-06-30 62.00164 -4.093406 -11.61581
2022-03-31 63.43781 1.914175 -8.191292
2021-12-31 61.249 3.69 -2.824
2021-09-30 65.7841 1.023974 2.049181
2021-09-30 65.7841 1.023974 3.100931

BIOC's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BIOC has a Quality Grade of D, ranking ahead of 15.64% of graded US stocks.
  • BIOC's asset turnover comes in at 1.212 -- ranking 14th of 81 Healthcare stocks.
  • SSY, LH, and MGLN are the stocks whose asset turnover ratios are most correlated with BIOC.

The table below shows BIOC's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.212 0.411 -0.069
2021-03-31 1.070 0.374 -0.312
2020-12-31 0.768 0.223 -1.341
2020-09-30 0.379 -0.323 -4.029
2020-06-30 0.239 -0.968 -4.770
2020-03-31 0.290 -0.903 -5.429

BIOC Price Target

For more insight on analysts targets of BIOC, see our BIOC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $12.00 Average Broker Recommendation 1.5 (Moderate Buy)

BIOC Stock Price Chart Interactive Chart >

Price chart for BIOC

BIOC Price/Volume Stats

Current price $0.76 52-week high $4.25
Prev. close $0.76 52-week low $0.70
Day low $0.73 Volume 71,900
Day high $0.77 Avg. volume 99,052
50-day MA $0.81 Dividend yield N/A
200-day MA $1.29 Market Cap 12.96M


BIOC Latest News Stream


Event/Time News Detail
Loading, please wait...

BIOC Latest Social Stream


Loading social stream, please wait...

View Full BIOC Social Stream

Latest BIOC News From Around the Web

Below are the latest news stories about BIOCEPT INC that investors may wish to consider to help them evaluate BIOC as an investment opportunity.

Biocept Reports Third Quarter 2022 Financial Results

SAN DIEGO, November 21, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2022 and provides a business update.

Yahoo | November 21, 2022

Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors

SAN DIEGO, November 18, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membership to eight. Ms. Dao-Haddock is a certified public accountant (CPA) with more than 20 years of financial and accounting experience. She will serve on Biocept’s Audit Committee.

Yahoo | November 18, 2022

Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System

SAN DIEGO, November 16, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a collaboration agreement to participate in an investigator-initiated, non-therapeutic pilot study to evaluate the cerebrospinal fluid tumor and immune cell microenvironment in patients with metastatic breast cancer and brain metastases and/or leptomeningeal disease. The study is designed to identify biomarkers associated with central nervous system (CNS

Yahoo | November 16, 2022

Biocept Reports Second Quarter 2022 Financial Results

SAN DIEGO, November 10, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2022 and provides a business update.

Yahoo | November 10, 2022

Biocept to Present at the LD Micro Main Event XV

SAN DIEGO, October 19, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that management will present at the LD Micro Main Event XV on Wednesday, October 26 at 2:30 p.m. Pacific time (5:30 p.m. Eastern time). The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles.

Yahoo | October 19, 2022

Read More 'BIOC' Stories Here

BIOC Price Returns

1-mo -0.21%
3-mo N/A
6-mo -51.59%
1-year -79.84%
3-year -85.19%
5-year -99.78%
YTD -79.01%
2021 -18.47%
2020 55.24%
2019 -66.74%
2018 -95.85%
2017 -10.39%

Continue Researching BIOC

Want to see what other sources are saying about Biocept Inc's financials and stock price? Try the links below:

Biocept Inc (BIOC) Stock Price | Nasdaq
Biocept Inc (BIOC) Stock Quote, History and News - Yahoo Finance
Biocept Inc (BIOC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8434 seconds.